GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » General and Admin. Expense

Viracta Therapeutics (STU:RYIS) General and Admin. Expense : €15.39 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Viracta Therapeutics's General and Admin. Expense for the three months ended in Mar. 2024 was €3.61 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €15.39 Mil.

Viracta Therapeutics General and Admin. Expense Historical Data

The historical data trend for Viracta Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics General and Admin. Expense Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
General and Admin. Expense
4.40 13.66 22.97 15.89

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.30 3.93 4.05 3.81 3.61

Viracta Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (STU:RYIS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » General and Admin. Expense
Comparable Companies
PIRS NRXP MRKR ENLV NCNA ORGS SRNEQ ABIO CADL RGLS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
VIRX:USA
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Website
https://www.viracta.com
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines